Business
Result of AGM
Result of AGM.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\nPoolbeg Pharma plc \n \nResults of Annual General Meeting\n13 June 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.\n \nEnquiries \n \n\n\n\n\nPoolbeg Pharma Plc \nJeremy Skillington, CEO \nIan O'Connell, CFO \n \n\n\n+44 (0) 207 183 1499 \n\n\n\n\nCavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) \nGeoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) \n \n\n\n+44 (0) 207 220 0500 \n\n\n\n\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking)\n \n\n\n+44 (0) 207 408 4090\n\n\n\n\nJ&E Davy (Joint Broker) \nAnthony Farrell, Niall Gilchrist \n \n\n\n+353 (0) 1 679 6363 \n\n\n\n\nOptimum Strategic Communications \nNick Bastin, Vici Rabbetts, Elena Bates \n \n\n\n+44 (0) 208 078 4357 \[email protected] \n\n\n\n\n \nAbout Poolbeg Pharma \n \nPoolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.\nPoolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.\nPoolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosop...